, Volume 24, Issue 7, pp 421-426
Date: 17 Sep 2012

Hypersensitivity to Nadroparin Calcium

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

The use of heparin to prevent or treat venous and pulmonary thrombosis, unstable angina and non-ST-elevation myocardial infarction is widely accepted. Nowadays, for many of these indications the unfractionated heparins (UFH; molecular weight [MW] 3–30 kDa) are largely being replaced by low-molecular-weight heparins (LMWHs; MW ≤5 kDa) because of the improved pharmacokinetic and pharmacodynamic properties as well as a better safety profile of the latter.[13] Adverse reactions to heparins include haemorrhages, osteopenia and immune-mediated hypersensitivity reactions, e.g. heparin-induced thrombocytopenia without and with (fatal) thrombosis,[410] immediate hypersensitivity reactions such as rhinoconjunctivitis,[11] asthma,[12] urticaria, angio-oedema and anaphylaxis,[1225] and delayed cutaneous reactions generally manifesting as infiltrated, eczematous plaques or leukocytoclastic vasculitis (type III Arthus reaction) at injection sites.[2635]

1. Case Report

A 47-year-old man with severe